Driving the Future of Biopharma
October 1, 2024
Biopharma companies procrastinating on sustainability measures risk falling behind, according to Cytiva’ Global Biopharma Sustainability Review
1 min read

October 1, 2024
Biopharma companies procrastinating on sustainability measures risk falling behind, according to Cytiva’ Global Biopharma Sustainability Review
1 min read
September 30, 2024
To celebrate the 10-year anniversary of The Medicine Maker, we look back on some of our most popular “Sitting Down With” interviews. These VIP interviews explore careers, motivations, and the love of the industry and drug development.
1 min read
September 27, 2024
From developments in cell culture media to enhancing the potency of monoclonal antibodies – check out our free eBook
1 min read
September 26, 2024
AstraZeneca’s FluMist is the first flu vaccine to be approved for self-administration.
1 min read
September 26, 2024
The analytical complexities that come with oligonucleotide manufacturing are difficult, but not impossible. The health benefits they bring will be worth it.
4 min read
September 25, 2024
Here’s how an mRNA-based approach can overcome the development challenges of designing protein therapeutics
7 min read
September 24, 2024
What’s going on with hot melt extrusion (HME)? We look at three recent studies that demonstrate the versatility of this manufacturing process for developing patient-centric dosage forms – from pediatric medicines to drug-loaded yarns.
3 min read
September 23, 2024
Supply chain lessons have been learned since COVID-19, so why are we seeing so many drug shortages? We speak with Noelle Lee, Vice President, Global Procurement and Drug Substance Supply Chain, pharma services, Thermo Fisher Scientific, about the challenges that supply chains face today and what the industry needs to do about it.
5 min read
September 20, 2024
Researchers use AI to reprogram glioblastoma cancer cells
1 min read
September 19, 2024
Regulators want more pediatric formulations. Companies often turn to liquids, but there are specific challenges that need to be considered.
4 min read
False
False